The Effect of Second Line FOLFOX Chemotherapy for Advanced Biliary Tract Cancer

DOI QR Code

진행성 담도암에서 2차 항암치료로 FOLFOX의 효과

Lee, Kyong Joo (Department of Internal Medicine, Yonsei University Wonju College of Medicine) ;
Park, Byung Kyu (Division of Gastroenterology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital)

Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5):v28-v37. https://doi.org/10.1093/annonc/mdw324
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281. https://doi.org/10.1056/NEJMoa0908721
Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013;49:329-335. https://doi.org/10.1016/j.ejca.2012.08.003
Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014;25:2328-2338. https://doi.org/10.1093/annonc/mdu162
Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021;22:690-701. https://doi.org/10.1016/S1470-2045(21)00027-9